Pressure Biosciences Inc
Pressure BioSciences, Inc. develops and sells high pressure technology-based instruments, consumables, and services for life sciences and other industries worldwide. The company's products/services are based on Ultra Shear Technology platform, which turns hydrophobic oil-based supplements, therapeutics, and other active ingredients to water-soluble, bioavailable, oil-in-water nano emulsion formul… Read more
Pressure Biosciences Inc (PBIO) - Net Assets
Latest net assets as of June 2024: $-37.23 Million USD
Based on the latest financial reports, Pressure Biosciences Inc (PBIO) has net assets worth $-37.23 Million USD as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($6.88 Million) and total liabilities ($44.11 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-37.23 Million |
| % of Total Assets | -541.16% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 64.03 |
Pressure Biosciences Inc - Net Assets Trend (2000–2023)
This chart illustrates how Pressure Biosciences Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Pressure Biosciences Inc (2000–2023)
The table below shows the annual net assets of Pressure Biosciences Inc from 2000 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $-32.75 Million | -0.21% |
| 2022-12-31 | $-32.69 Million | -47.18% |
| 2021-12-31 | $-22.21 Million | -31.28% |
| 2020-12-31 | $-16.92 Million | -40.33% |
| 2019-12-31 | $-12.06 Million | -96.82% |
| 2018-12-31 | $-6.13 Million | +58.11% |
| 2017-12-31 | $-14.62 Million | -74.43% |
| 2016-12-31 | $-8.38 Million | -5.09% |
| 2015-12-31 | $-7.98 Million | -287.32% |
| 2014-12-31 | $-2.06 Million | -4.67% |
| 2013-12-31 | $-1.97 Million | -27.78% |
| 2012-12-31 | $-1.54 Million | -277.45% |
| 2011-12-31 | $-408.00K | -122.54% |
| 2010-12-31 | $1.81 Million | -32.66% |
| 2009-12-31 | $2.69 Million | +26.55% |
| 2008-12-31 | $2.12 Million | -67.39% |
| 2007-12-31 | $6.51 Million | -19.74% |
| 2006-12-31 | $8.12 Million | -28.60% |
| 2005-12-31 | $11.37 Million | -51.42% |
| 2004-12-31 | $23.39 Million | +124.60% |
| 2003-12-31 | $10.41 Million | -17.52% |
| 2002-12-31 | $12.63 Million | -6.05% |
| 2001-12-31 | $13.44 Million | +73.42% |
| 2000-12-31 | $7.75 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Pressure Biosciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 16902863900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $136.27 Million | % |
| Total Equity | $-32.75 Million | 100.00% |
Pressure Biosciences Inc Competitors by Market Cap
The table below lists competitors of Pressure Biosciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Eckoh Plc
LSE:ECK
|
$20.49K |
|
Khiron Life Sciences Corp
PINK:KHRNF
|
$20.49K |
|
Notoria
WAR:NTS
|
$20.54K |
|
EUTELSAT COMM.
MU:E3B
|
$20.56K |
|
BHB BRAUHOLDING
MU:B9B
|
$20.48K |
|
Gamer Pakistan Inc. Common Stock
PINK:GPAK
|
$20.46K |
|
SDX Energy plc
PINK:SDXEF
|
$20.46K |
|
Namunukula Plantations PLC
CM:NAMUN0000
|
$20.43K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Pressure Biosciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from -32,686,371 to -32,753,829, a change of -67,458.
- Net loss of 29,314,298 reduced equity.
- New share issuances of 150,000 increased equity.
- Other factors increased equity by 29,096,840.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-29.31 Million | -89.5% |
| Share Issuances | $150.00K | +0.46% |
| Other Changes | $29.10 Million | +88.83% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Pressure Biosciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $-0.16 | $0.00 | x |
| 2014-12-31 | $-0.11 | $0.00 | x |
| 2016-12-31 | $-0.27 | $0.00 | x |
| 2017-12-31 | $-10.89 | $0.00 | x |
| 2018-12-31 | $-3.64 | $0.00 | x |
| 2019-12-31 | $-4.73 | $0.00 | x |
| 2020-12-31 | $-4.06 | $0.00 | x |
| 2021-12-31 | $-2.44 | $0.00 | x |
| 2022-12-31 | $-2.39 | $0.00 | x |
| 2023-12-31 | $-0.93 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Pressure Biosciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1482.19%
- • Asset Turnover: 1.88x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (6.72%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2001 | 25.65% | 15.80% | 1.02x | 1.59x | $2.10 Million |
| 2004 | 54.35% | 3078.21% | 0.02x | 1.06x | $10.37 Million |
| 2005 | 14.11% | 1513.21% | 0.01x | 1.29x | $467.50K |
| 2013 | 0.00% | -271.70% | 1.36x | 0.00x | $-3.89 Million |
| 2014 | 0.00% | -335.52% | 0.79x | 0.00x | $-4.41 Million |
| 2015 | 0.00% | -412.49% | 1.00x | 0.00x | $-6.62 Million |
| 2016 | 0.00% | -136.96% | 1.22x | 0.00x | $-1.87 Million |
| 2017 | 0.00% | -478.27% | 1.04x | 0.00x | $-9.25 Million |
| 2018 | 0.00% | -394.62% | 1.02x | 0.00x | $-9.09 Million |
| 2019 | 0.00% | -644.25% | 1.00x | 0.00x | $-10.46 Million |
| 2020 | 0.00% | -1311.29% | 0.53x | 0.00x | $-14.31 Million |
| 2021 | 0.00% | -1006.48% | 0.71x | 0.00x | $-17.93 Million |
| 2022 | 0.00% | -929.64% | 0.86x | 0.00x | $-12.81 Million |
| 2023 | 0.00% | -1482.19% | 1.88x | 0.00x | $-26.04 Million |
Industry Comparison
This section compares Pressure Biosciences Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Pressure Biosciences Inc (PBIO) | $-37.23 Million | 25.65% | N/A | $20.48K |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |